EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study

Nicholas A Marston iD, Brian A Bergmark iD, Thomas A Prohaska, Filipe A Moura iD, André Zimerman iD, Veronica J Alexander iD, Yu Mi Kang iD, Julia Weinland, Xinhui Ran iD, Sabina A Murphy iD, Shuanglu Zhang iD, Dan Li und 13 weitere

Circulation · 19.05.2026 · 153 (20) · 1539-1548

DOI: 10.1161/circulationaha.126.080012 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 19.05.2026. Verfasst von Nicholas A Marston und 24 weiteren Autor:innen. Beteiligte Einrichtung: Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (N.A.M., B.A.B., X.R…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Apolipoprotein C-III, Oligonucleotides, Hypertriglyceridemia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Ionis Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Whether lowering triglyceride-rich lipoproteins and remnant cholesterol favorably modifies coronary atherosclerosis is unclear. Olezarsen, an antisense oligonucleotide that targets apolipoprotein C-III, reduces triglycerides by ~60% and remnant cholesterol by ~70%, has a neutral effect on LDL (low-density lipoprotein) cholesterol (LDL-C), and reduces apoB (apolipoprotein B) by ~15% in moderate hypertriglyceridemia. We investigated the effect of olezarsen on coronary plaque in adults with largely moderate hypertriglyceridemia. METHODS: We conducted a coronary computed tomography angiography study within Essence-TIMI 73b, a randomized, placebo-controlled trial of olezarsen versus placebo that enrolled patients between November 2022 and February 2024. Inclusion criteria were triglycerides ≥150 mg/dL (2.26 mmol/L), presence of or high risk for cardiovascular disease, and, for this imaging study, noncalcified plaque on baseline coronary computed tomography angiography. The primary end point was percent change from baseline to 12 months in noncalcified plaque volume. RESULTS: Of 468 participants (349 olezarsen, 119 placebo), the median age was 63 years (interquartile range, 56–70); 31% were women, and 97% received lipid-lowering therapy. Median baseline triglycerides were 249 mg/dL (interquartile range, 197–331), and remnant cholesterol was 53 mg/dL (interquartile range, 38–76). Median baseline noncalcified plaque volume was 125.3 mm³ (interquartile range, 63.2–213.3). At 6 months, olezarsen reduced triglycerides by 63.9%, remnant cholesterol by 71.9%, and apoB by 16.0% over placebo, with no difference in LDL-C. The percent change in noncalcified plaque volume from baseline to month 12 did not differ between olezarsen and placebo (placebo-adjusted least-squares mean difference, 2.98% [95% CI, −3.4 to 9.3]; p=0.36). No significant differences between olezarsen and placebo were observed for changes in low-attenuation, calcified, or total plaque volumes at 12 months. CONCLUSIONS: Despite substantial triglyceride and remnant cholesterol lowering, treatment with olezarsen for 12 months on top of standard-of-care lipid-lowering therapy in patients with largely moderate hypertriglyceridemia did not affect noncalcified coronary plaque volume. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05610280.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseApolipoprotein C-IIIOligonucleotidesHypertriglyceridemiaHumansMiddle AgedFemaleMaleAgedComputed Tomography AngiographyPlaque, AtheroscleroticTriglyceridesDouble-Blind MethodCoronary AngiographyTreatment Outcome

Stichwörter der Autor:innen

apolipoprotein C-IIIatherosclerosiscoronary computerized tomography (CT)coronary plaquelipid loweringtriglycerides

Substanzen

Apolipoprotein C-IIIAPOC3 protein, humanTriglyceridesOligonucleotidesolezarsen

Autor:innen und Institutionen

  • Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (N.A.M., B.A.B., X.R., S.A.M., S.Z., R.P.G., M.S.S.).
  • Harvard Medical School, Boston, MA (N.A.M., B.A.B., Y.M.K., B.F., M.T.L., R.P.G., M.S.S.).
  • Ionis Pharmaceuticals, Carlsbad, CA (T.A.P., V.J.A., J.W., D.L., S.T.).
  • Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT (F.A.M.).
  • VA Connecticut Healthcare System, West Haven, CT (F.A.M.).
  • MOVE Academic Research Organization, Hospital Moinhos de Vento, Moinhos de Vento Medical School, Porto Alegre, Brazil (A.Z.).

ORCID-Profile: Nicholas A Marston, Brian A Bergmark, Filipe A Moura, André Zimerman, Veronica J Alexander, Yu Mi Kang, Xinhui Ran, Sabina A Murphy, Shuanglu Zhang, Maciej Banach, Erik S G Stroes, Robert Kiss, Daniel Gaudet, Michal Vrablik, Jeroen J Bax, Matthew J Budoff, Borek Foldyna, Michael T Lu, Sotirios Tsimikas, Robert P Giugliano, Marc S Sabatine

Förderung

  • Ionis Pharmaceuticals

Zitieren

APA

Marston, N. A., Bergmark, B. A., Prohaska, T. A., Moura, F. A., Zimerman, A., Alexander, V. J., Kang, Y. M., Weinland, J., Ran, X., Murphy, S. A., Zhang, S., Li, D., Banach, M., Stroes, E. S. G., Kiss, R., Gaudet, D., Vrablik, M., Goudev, A., Bax, J. J., …, & Sabatine, M. S. (2026). Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study. Circulation, 153(20), 1539-1548. https://doi.org/10.1161/circulationaha.126.080012

Vancouver

Marston NA, Bergmark BA, Prohaska TA, Moura FA, Zimerman A, Alexander VJ, et al. Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study. Circulation. 2026;153(20):1539-1548. doi:10.1161/circulationaha.126.080012

BibTeX
@article{Marston2026,
  author = {Marston, Nicholas A and Bergmark, Brian A and Prohaska, Thomas A and Moura, Filipe A and Zimerman, André and Alexander, Veronica J and Kang, Yu Mi and Weinland, Julia and Ran, Xinhui and Murphy, Sabina A and Zhang, Shuanglu and Li, Dan and Banach, Maciej and Stroes, Erik S G and Kiss, Robert and Gaudet, Daniel and Vrablik, Michal and Goudev, Assen and Bax, Jeroen J and Budoff, Matthew J and Foldyna, Borek and Lu, Michael T and Tsimikas, Sotirios and Giugliano, Robert P and Sabatine, Marc S},
  title = {Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study},
  journal = {Circulation},
  year = {2026},
  volume = {153},
  number = {20},
  pages = {1539--1548},
  doi = {10.1161/circulationaha.126.080012}
}
Kostenlos starten →